27 Assets for Licensing【DrugTimes BD Project】

If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.

Email: BD@drugtimes.cn

For more assets or BD opportunities, please kindly visit: https://www.drugtimes.cn/english-content/

Thank you very much! ~

（1）Orally bioavailable selective THR-β small-molecule agonist for MASH

https://www.drugtimes.cn/2026/07/13/%e3%80%90asset-for-licensing%e3%80%91orally-bioavailable-selective-thr-%ce%b2-small-molecule-agonist-for-mash/

（2）Novel CD19/BCMA/CD3 trispecific antibody (TsAb) for autoimmune diseases

https://www.drugtimes.cn/2026/07/13/%e3%80%90asset-for-licensing%e3%80%91novel-cd19-bcma-cd3-trispecific-antibody-tsab-for-autoimmune-diseases/

（3）First-in-class CDH17/4-1BB bispecific antibody (bsAb)

https://www.drugtimes.cn/2026/07/13/%e3%80%90asset-for-licensing%e3%80%91first-in-class-cdh17-4-1bb-bispecific-antibody-bsab/

（4）Novel LIV-1-targeted ADC armed with optimized TOPO1 inhibitor payload

https://www.drugtimes.cn/2026/07/12/%e3%80%90asset-for-licensing%e3%80%91novel-liv-1-targeted-adc-armed-with-optimized-topo1-inhibitor-payload/

（5）Novel CDH6-targeted ADC conjugated with TOPO1 inhibitor payload

https://www.drugtimes.cn/2026/07/12/%e3%80%90asset-for-licensing%e3%80%91/

（6）Novel Claudin6-targeted ADC armed with optimized TOPO1 inhibitor payload

https://www.drugtimes.cn/2026/07/12/%e3%80%90asset-for-licensing%e3%80%91novel-claudin6-targeted-adc-armed-with-optimized-topo1-inhibitor-payload/

（7）Novel pan-RAS molecular glue degrader for multiple solid tumors

https://www.drugtimes.cn/2026/07/12/%e3%80%90asset-for-licensing%e3%80%91novel-pan-ras-molecular-glue-degrader-for-multiple-solid-tumors/

（8）Orally bioavailable selective PI3Kα small-molecule inhibitor

https://www.drugtimes.cn/2026/07/12/%e3%80%90asset-for-licensing%e3%80%91orally-bioavailable-selective-pi3k%ce%b1-small-molecule-inhibitor/

（9）Novel STEAP1/PSMA/CD3 trispecific antibody for Prostate Cancer

https://www.drugtimes.cn/2026/07/12/%e3%80%90asset-for-licensing%e3%80%91novel-steap1-psma-cd3-trispecific-antibody-for-prostate-cancer/

（10）Orally bioavailable selective PARG small-molecule inhibitor

https://www.drugtimes.cn/2026/07/12/%e3%80%90asset-for-licensing%e3%80%91orally-bioavailable-selective-parg-small-molecule-inhibitor/

（11）Orally bioavailable selective KIF18A small-molecule inhibitor

https://www.drugtimes.cn/2026/07/12/%e3%80%90asset-for-licensing%e3%80%91orally-bioavailable-selective-kif18a-small-molecule-inhibitor/

（12）Orally bioavailable selective WRN small-molecule inhibitor

https://www.drugtimes.cn/2026/07/12/%e3%80%90asset-for-licensing%e3%80%91orally-bioavailable-selective-wrn-small-molecule-inhibitor/

（13）Orally available selective KAT6A/B small molecule inhibitor

https://www.drugtimes.cn/2026/07/12/%e3%80%90asset-for-licensing%e3%80%91orally-available-selective-kat6a-b-small-molecule-inhibitor/

（14）Orally bioavailable selective KRAS G12D small molecule inhibitor

https://www.drugtimes.cn/2026/07/12/%e3%80%90asset-for-licensing%e3%80%91orally-bioavailable-selective-kras-g12d-small-molecule-inhibitor/

（15）Novel multi-functional recombinant polypeptide with antibacterial, anti-inflammatory and anti-HPV activities for women’s health

https://www.drugtimes.cn/2026/07/11/%e3%80%90asset-for-licensing%e3%80%91novel-multi-functional-recombinant-polypeptide-with-antibacterial-anti-inflammatory-and-anti-hpv-activities-for-womens-health/

(16) Novel gastric mucosa-protective recombinant polypeptide for Chronic gastritis and chronic atrophic gastritis

https://www.drugtimes.cn/2026/07/11/%e3%80%90asset-for-licensing%e3%80%91novel-gastric-mucosa-protective-recombinant-polypeptide-for-chronic-gastritis-and-chronic-atrophic-gastritis/

(17) Novel antibacterial and anti-inflammatory recombinant polypeptide for HAP

https://www.drugtimes.cn/2026/07/11/%e3%80%90asset-for-licensing%e3%80%91novel-antibacterial-and-anti-inflammatory-recombinant-polypeptide-for-hap/

(18) Novel anti-inflammatory and anti-infective recombinant polypeptide

https://www.drugtimes.cn/2026/07/11/%e3%80%90asset-for-licensing%e3%80%91novel-anti-inflammatory-and-anti-infective-recombinant-polypeptide/

(19) Potent and selective oral PCSK9 small-molecule inhibitor

https://www.drugtimes.cn/2026/07/11/%e3%80%90asset-for-licensing%e3%80%91potent-and-selective-oral-pcsk9-small-molecule-inhibitor/

(20) Potent and selective oral sEH small-molecule inhibitor

https://www.drugtimes.cn/2026/07/11/%e3%80%90asset-for-licensing%e3%80%91potent-and-selective-oral-seh-small-molecule-inhibitor/

(21) Potent and selective oral PARP1 small-molecule inhibitor

https://www.drugtimes.cn/2026/07/11/%e3%80%90asset-for-licensing%e3%80%91potent-and-selective-oral-parp1-small-molecule-inhibitor/

(22) Selective oral CYP11A1 small-molecule inhibitor

https://www.drugtimes.cn/2026/07/11/%e3%80%90asset-for-licensing%e3%80%91selective-oral-cyp11a1-small-molecule-inhibitor/

(23) Novel PDE3A-targeting dual-protein molecular glue degrader

https://www.drugtimes.cn/2026/07/11/%e3%80%90asset-for-licensing%e3%80%91novel-pde3a-targeting-dual-protein-molecular-glue-degrader/

(24) CCR8-targeting mAb in clinical stage for solid tumors

https://www.drugtimes.cn/2026/07/11/%e3%80%90asset-for-licensing%e3%80%91ccr8-targeting-mab-in-clinical-stage-for-solid-tumors/

(25) Claudin18.2/CD3 bispecific T-cell engager (TCE)

https://www.drugtimes.cn/2026/07/11/%e3%80%90asset-for-licensing%e3%80%91claudin18-2-cd3-bispecific-t-cell-engager-tce/

(26) Oral small-molecule PD-L1 inhibitor for solid tumor treatment

https://www.drugtimes.cn/2026/07/09/%e3%80%90asset-for-licensing%e3%80%91oral-small-molecule-pd-l1-inhibitor-for-solid-tumor-treatment/

(27) LY6G6D-targeting antibodies for advanced malignant solid tumors

https://www.drugtimes.cn/2026/07/09/%e3%80%90asset-for-licensing%e3%80%91ly6g6d-targeted-antibodies-for-advanced-malignant-solid-tumors/

#DrugTimes #drugdiscovery #drugdevelopment #businessdevelopment #LIDLO #LIDIPO #LIDMA #WorldBDDay #Pharmaceuticals #biotech #DrugTimesRoadshow #Assetforlicensing #BD #NewCo #Searchandevaluation